Mega CapHealthcareDividend

PFE — Pfizer Inc.

Pharmaceuticals · Founded 1849 · New York, New York · CEO: Albert Bourla

Pfizer is one of the world's largest pharmaceutical companies, with a diversified portfolio spanning oncology, immunology, rare diseases, vaccines, and hospital medicines. The company became globally prominent during the COVID-19 pandemic through its co-developed mRNA vaccine (Comirnaty) with BioNTech and antiviral pill Paxlovid. Post-pandemic, Pfizer has focused on restoring growth through acquisitions including Seagen (oncology) and deploying its substantial cash reserves. The company faces significant patent cliffs on several major drugs in the late 2020s.

How Pfizer Inc. Makes Money

Branded pharmaceutical drug sales across oncology, immunology, internal medicine, and rare diseases

Vaccine revenue from Prevnar (pneumococcal) and COVID vaccine Comirnaty

Paxlovid antiviral COVID treatment sales to governments and pharmacies

Royalty and milestone revenue from licensing and co-development agreements

Key Metrics Investors Watch

Excluding COVID product revenue growth (non-COVID base business trajectory)
Oncology pipeline progression and FDA approval rates
Patent cliff timeline for key drugs (Eliquis, Ibrance) in late 2020s
Seagen integration synergies and oncology revenue contribution
R&D spend efficiency (new molecular entities entering Phase 3)

Competitive Advantages

One of the largest pharmaceutical R&D budgets and drug pipelines in the industry
Prevnar franchise dominates the pneumococcal vaccine market globally
mRNA vaccine platform co-developed with BioNTech provides foundation for future vaccine products
Global commercial infrastructure enables rapid deployment of new products at scale

Key Risks

Significant revenue declines from COVID products as pandemic subsides
Multiple major drugs face patent cliffs by 2030, exposing revenue to generic competition
Integration risk from large acquisitions including Seagen ($43B) at a high price
R&D pipeline failures in oncology and rare diseases create earnings uncertainty

Dividend & Capital Return

Pfizer is a high-dividend-yield pharmaceutical stock that has historically maintained and grown its quarterly dividend even during revenue headwinds.

I Document Every Trade — Even the Losses

Options record: 1W-8L. Net worth: 100% GSE preferred. Get the unfiltered updates.

Unsubscribe anytime. I respect your inbox more than Congress respects property rights.

Frequently Asked Questions

What are Pfizer's biggest drugs?

Pfizer's top revenue products include Paxlovid (COVID antiviral), Comirnaty (COVID vaccine), Eliquis (blood thinner, co-marketed with BMS), Prevnar 20 (pneumococcal vaccine), and Ibrance (breast cancer). Seagen's antibody-drug conjugate portfolio is a growing addition. This is educational content, not financial advice.

Does Pfizer pay a good dividend?

Pfizer pays one of the higher dividend yields among large-cap pharma stocks. The quarterly dividend has been maintained through periods of revenue volatility, including post-COVID revenue normalization. This is educational content, not financial advice.

What is the patent cliff issue for Pfizer?

Several major Pfizer drugs, including Eliquis and Ibrance, lose patent protection in the late 2020s, at which point generic competition typically reduces brand revenue by 80-90%. Pfizer must offset these losses with new pipeline drugs and acquisitions. This is educational content, not financial advice.

Why did Pfizer acquire Seagen?

Seagen is a leader in antibody-drug conjugate (ADC) technology for cancer treatment. Pfizer acquired Seagen in 2023 for $43 billion to strengthen its oncology portfolio ahead of upcoming patent expirations on other key drugs. This is educational content, not financial advice.

Is Pfizer a value stock?

Post-pandemic, many investors view Pfizer as a value play given its low valuation multiple and high dividend yield. Bears cite the patent cliff, acquisition risks, and COVID revenue normalization. Bulls emphasize the pipeline and Seagen-driven oncology growth. This is educational content, not financial advice.

Related Stocks

JNJ

Johnson & Johnson

Healthcare

Johnson & Johnson is a global healthcare company operating in pharmaceuticals (Innovative Medicine) and medical devices (MedTech). Following the spin-off of its consumer health division as Kenvue in 2023, JNJ is now focused on higher-growth, higher-margin healthcare segments.

ABBV

AbbVie Inc.

Healthcare

AbbVie is a global biopharmaceutical company focused on immunology, oncology, neuroscience, and eye care. Spun off from Abbott Laboratories in 2013, AbbVie is best known for Humira (the world's best-selling drug of all time) and its successor drugs Skyrizi and Rinvoq.

MRK

Merck & Co., Inc.

Healthcare

Merck is a global pharmaceutical and animal health company known for Keytruda, the world's best-selling cancer immunotherapy drug. The company has a strong pipeline in oncology, vaccines, and cardiometabolic diseases and operates one of the largest animal health businesses globally.

BMY

Bristol-Myers Squibb Company

Healthcare

Bristol-Myers Squibb is a global biopharmaceutical company focused on serious diseases including oncology, hematology, cardiovascular, and immunology. Its acquisition of Celgene in 2019 for $74 billion dramatically expanded BMS into blood cancer treatments, adding Revlimid, Pomalyst, and Abraxane. BMS also markets Opdivo (cancer immunotherapy), Eliquis (anticoagulant, co-marketed with Pfizer), and Orencia (rheumatoid arthritis). The company faces significant patent cliffs as Revlimid generic competition accelerates.

MRNA

Moderna, Inc.

Healthcare

Moderna is a biotechnology company that pioneered messenger RNA (mRNA) therapeutics and vaccines. Its COVID-19 vaccine (Spikevax) was authorized in December 2020 and became one of the best-selling pharmaceutical products in history. Post-pandemic, Moderna is deploying its mRNA platform to develop vaccines for respiratory viruses (RSV, flu-COVID combination), personalized cancer vaccines (with Merck), and rare diseases. The company is in a critical transition from COVID dependence to a diversified pipeline.

Recommended Resources

Tools & books I actually use and recommend

SeekingAlpha Premium

Quant ratings, earnings transcripts, and the stock analysis community where I published 300+ articles.

Try SeekingAlpha

The Intelligent Investor

Ben Graham's timeless guide to value investing. The book Warren Buffett calls "the best investing book ever written."

View on Amazon

Interactive Brokers

Low commissions, global market access, and professional-grade tools. This is where I hold my positions.

Open an Account

Some links above are affiliate links. I only recommend products I personally use. See my full disclosures.

Keep Exploring

Hub

All Stocks

Browse all 134 stock profiles by sector.

Best Stocks For Beginners

Curated stock picks for new investors by goal.

Financial Glossary

Understand the terms investors use every day.

Stock vs ETF

Individual stocks vs ETFs — which is right for you?

ETF Profiles

Deep dives on 90+ ETFs across every category.

Buying Your First Stock

How to open a brokerage and buy your first share.

Browse All 134 Stock Profiles

Company information is based on publicly available disclosures and widely-known business facts. No specific price, earnings, or real-time market data is included. This is educational content — not investment advice.